LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

67%

33%

313 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. veebr 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22. veebr 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22. veebr 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22. veebr 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22. veebr 2026, 23:21 UTC

Tulu

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22. veebr 2026, 23:20 UTC

Tulu

Nickel Industries 2025 Operating Profit US$126.4 Million

22. veebr 2026, 23:19 UTC

Tulu

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22. veebr 2026, 23:19 UTC

Tulu

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22. veebr 2026, 23:18 UTC

Tulu

Nickel Industries Won't Pay a Final Dividend

22. veebr 2026, 23:16 UTC

Tulu

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22. veebr 2026, 21:35 UTC

Tulu

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22. veebr 2026, 21:34 UTC

Tulu

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22. veebr 2026, 21:34 UTC

Tulu

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22. veebr 2026, 21:33 UTC

Tulu

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22. veebr 2026, 21:33 UTC

Tulu

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22. veebr 2026, 21:28 UTC

Tulu

Ampol Final Dividend A$0.60/Share

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Revenue A$31.37 Billion, Down 10%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22. veebr 2026, 21:28 UTC

Tulu

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21. veebr 2026, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20. veebr 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. veebr 2026, 22:12 UTC

Tulu

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. veebr 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. veebr 2026, 21:23 UTC

Tulu

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. veebr 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. veebr 2026, 21:01 UTC

Omandamised, ülevõtmised, äriostud

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. veebr 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

313 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.